 |
|
|
| |
Safety, pharmacokinetics, and antiviral activity of the next-generation hepatitis B core inhibitor ABI-H3733 in patients with hepatitis B e antigen negative chronic hepatitis B infection: Preliminary results from a randomized, blinded, Phase 1b study
|
| |
| |
EASL 2023 June 21-24 Vienna
Edward J. Gane1, Alina Jucov2, Krum Katzarov3, Oana Sandulescu4, Ran Yan5, Kathryn M. Kitrinos5, Jieming Liu5, Katie Zomorodi5, Luisa M. Stamm5, Steven J. Knox5, Michele Anderson5, Grace Wang5, Radoslava Tsrancheva6, Anca Streinu-Cercel4
1University of Auckland, Auckland, New Zealand; 2ARENSIA Exploratory Medicine GmbH, Düsseldorf, Germany, and Department of Gastroenterology, State University of Medicine and Pharmacy, Chisinau, Republic of Moldova; 3Department of Gastroenterology, HPB and Transplant Surgery, Military Medical Academy, Sofia, Bulgaria; 4Carol Davila University of Medicine and Pharmacy; National Institute for Infectious Diseases "Prof. Dr. Matei Bals," Bucharest, Romania; 5Assembly Biosciences, Inc., South San Francisco, CA, USA; 6Diagnostic Consultative Center Aleksandrovska, Sofia, Bulgaria
|
| |
|
|
|
|
|
